All Title Author
Keywords Abstract

PLOS Medicine  2005 

The Development of Vaginal Microbicides for the Prevention of HIV Transmission

DOI: 10.1371/journal.pmed.0020142

Full-Text   Cite this paper   Add to My Lib



[1]  Coordinating Committee of the Global HIV/ AIDS Vaccine Enterprise (2005) The Global HIV/AIDS Vaccine Enterprise: Scientific strategic plan. PLoS Med 2: e25.
[2]  Horton R (2003 September 23) AIDS: The elusive vaccine. New York Rev Books 51(14): 53–58.
[3]  Weller S, Davis K (2002) Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002: CD003255.
[4]  Hicks DR, Martin LS, Getchell JP, Heath JL, Francis DP, et al. (1985) Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 2: 1422–1423.
[5]  Miller CJ, Alexander NJ, Gettie A, Hendrickx AG, Marx PA (1992) The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil Steril 57: 1126–1128.
[6]  Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, et al. (1992) Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268: 477–482.
[7]  Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, et al. (1998) A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 339: 504–510.
[8]  Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, et al. (1998) Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 17: 327–331.
[9]  Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 360: 971–977.
[10]  Krebs FC, Miller SR, Catalone BJ, Welsh PA, Malamud D, et al. (2000) Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: Comparative sensitivity of primary human vaginal keratinocytes. Antimicrob Agents Chemother 44: 1954–1960.
[11]  McClure MO, Moore JP, Blanc DF, Scotting P, Cook GM, et al. (1992) Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res Hum Retroviruses 8: 19–26.
[12]  Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, et al. (1984) Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226: 172–174.
[13]  Weber J, Nunn A, O'Connor T, Jeffries D, Kitchen V, et al. (2001) ‘Chemical condoms’ for the prevention of HIV infection: Evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15: 1563–1568.
[14]  Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, et al. (2003) Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17: 321–329.
[15]  Rosenstein IJ, Stafford MK, Kitchen VS, Ward H, Weber JN, et al. (1998) Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis 177: 1386–1390.
[16]  Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, et al. (2001) Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 32: 476–482.
[17]  Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343–346.
[18]  Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, et al. (2004) Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306: 485–487.


comments powered by Disqus